Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
16. Februar 2022 09:40 ET
|
Hillstream BioPharma Inc.
-Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease- -Evidence implicates ferroptosis, an emerging iron-mediated cell...
Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
23. April 2020 08:00 ET
|
Immunomedics, Inc.
First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...